THE PRACTICAL BENEFITS OF PHARMACOKINETICS IN THE USE OF ANTINEOPLASTIC AGENTSERLICHMAN C; DONEHOWER RC; CHABNER BA et al.1980; CANCER CHEMOTHER. PHARMACOL.; DEU; DA. 1980; VOL. 4; NO 3; PP. 139-145; BIBL. 77 REF.Article

APPLICATION OF A SIMPLE COMPETITIVE PROTEIN-BINDING ASSAY TECHNIQUE TO THE PHARMACOKINETICS OF N-(PHOSPHONACETYL)-L-ASPARTATE IN HUMANSERLICHMAN C; STRONG JM; CHABNER BA et al.1980; CANCER RES.; USA; DA. 1980; VOL. 40; NO 6; PP. 1902-1906; BIBL. 16 REF.Article

COMPETITIVE PROTEIN BINDING ASSAY OF METHOTREXATEERLICHMAN C; DONEHOWER RC; MYERS CE et al.1982; METHODS ENZYMOL.; ISSN 0076-6879; USA; DA. 1982; VOL. 84; PP. 447-458; BIBL. 22 REF.Article

Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived miceERLICHMAN, C; VIDGEN, D.Cancer research (Baltimore). 1984, Vol 44, Num 11, pp 5369-5375, issn 0008-5472Article

Effects of 5-flourouracil and leucovorin in spheroids : a model for solid tumoursERLICHMAN, C; WU, A.Anticancer research. 1991, Vol 11, Num 2, pp 671-675, issn 0250-7005, 5 p.Article

Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694 : cytotoxic and biochemical effectsPRESSACCO, J; ERLICHMAN, C.Biochemical pharmacology. 1993, Vol 46, Num 11, pp 1989-1997, issn 0006-2952Article

Resistance of MGH-U1 bladder cancer spheroids to vincristineERLICHMAN, C; WU, A.Anticancer research. 1992, Vol 12, Num 4, pp 1233-1236, issn 0250-7005Article

FAILURE OF 5-DAY VINBLASTINE INFUSION IN THE TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY BREAST CANCERTANNOCK I; ERLICHMAN C; PERRAULT D et al.1982; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1982; VOL. 66; NO 9; PP. 1783-1784; BIBL. 1 REF.Article

PHASE I- PHASE II TRIAL OF N-PHOSPHONACETYL-L-ASPARTIC ACID GIVEN BY INTRAVENOUS INFUSION AND 5-FLUOROURACIL GIVEN BY BOLUS INJECTIONERLICHMAN C; DONEHOWER RC; SPEYER JL et al.1982; J. NATL. CANCER INST.; ISSN 0027-8874; USA; DA. 1982; VOL. 68; NO 2; PP. 227-231; BIBL. 19 REF.Article

PERIPHERAL LEUKOCYTES AS INDICATORS OF THE ENZYMATIC EFFECTS OF N-(PHOSPHONACETYL)-L-ARPARTIC ACID (PALA) ON HUMAN L-ASPARTATE TRANSCARBAMOYLASE (ATCASE) ACTIVITYKENSLER TW; ERLICHMAN C; JAYARAM HN et al.1980; CANCER TREATM. REP.; USA; DA. 1980; VOL. 64; NO 8-9; PP. 967-973; BIBL. 25 REF.Article

COMBINED RADICAL RADIATION THERAPY AND CHEMOTHERAPY FOR PRIMARY SQUAMOUS CELL CARCINOMA OF THE ANAL CANALCUMMINGS BJ; RIDER WD; HARWOOD AR et al.1982; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1982; VOL. 66; NO 3; PP. 489-492; BIBL. 11 REF.Article

Treatment of advanced gastric carcinoma with mitomycin and doxorubicinDALLEY, D; ERLICHMAN, C; FINE, S et al.Cancer treatment reports. 1986, Vol 70, Num 7, pp 897-898, issn 0361-5960Article

Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenograftsERLICHMAN, C; VIDGEN, D; WU, A et al.Journal of the National Cancer Institute. 1985, Vol 75, Num 3, pp 499-505, issn 0027-8874Article

Biochemical effects of folate-based inhibitors of thymidylate synthase in MGU-U1 cellsMITROVSKI, B; PRESSACCO, J; MANDELBAUM, S et al.Cancer chemotherapy and pharmacology. 1994, Vol 35, Num 2, pp 109-114, issn 0344-5704Article

A bioassay to measure cytotoxicity of plasma from patients treated with mitomycin CMARSHALL, R. S; ERLICHMAN, C; RAUTH, A. M et al.Cancer research (Baltimore). 1985, Vol 45, Num 11, pp 5939-5943, issn 0008-5472Article

Cytotoxic and biochemical implications of combining AZT and AG-331PRESSACCO, J; MITROVSKI, B; ERLICHMAN, C et al.Cancer chemotherapy and pharmacology. 1995, Vol 35, Num 5, pp 387-390, issn 0344-5704Article

ICI D1694 and idoxuridine : a synergistic antitumor combinationPRESSACCO, J; HEDLEY, D. W; ERLICHMAN, C et al.Cancer research (Baltimore). 1994, Vol 54, Num 14, pp 3772-3778, issn 0008-5472Article

Allopurinol mouthwash for prevention of fluorouracil-induced stomatitisVAN DER VLIET, W; ERLICHMAN, C; ELHAKIM, T et al.Clinical pharmacy. 1989, Vol 8, Num 9, pp 655-658, issn 0278-2677Article

Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenograftsERLICHMAN, C; VIDGEN, D; WU, A et al.Journal of the National Cancer Institute. 1985, Vol 75, Num 3, pp 499-505, issn 0027-8874Article

Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancerFINE, S; ERLICHMAN, C; KAIZER, L et al.Breast cancer research and treatment. 1994, Vol 30, Num 2, pp 205-209, issn 0167-6806Article

Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acidSTEINBERG, J; ERLICHMAN, C; GADALLA, T et al.European journal of cancer. Part A. 1992, Vol 28, Num 11, pp 1817-1820Article

RECPAM analysis of prognostic factors in patients with stage III breast cancerERLICHMAN, C; WARDE, P; GADALLA, T et al.Breast cancer research and treatment. 1990, Vol 16, Num 3, pp 231-242, issn 0167-6806, 12 p.Article

Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinomaERLICHMAN, C; RAUTH, A. M; BATTISTELLA, R et al.Canadian journal of physiology and pharmacology. 1987, Vol 65, Num 3, pp 407-411, issn 0008-4212Article

Comparison of potential markers of farnesyltransferase inhibitionADJEI, A. A; DAVIS, J. N; ERLICHMAN, C et al.Clinical cancer research. 2000, Vol 6, Num 6, pp 2318-2325, issn 1078-0432Article

Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancerERLICHMAN, C; SOLDIN, S. J; THIESSEN, J. J et al.Cancer chemotherapy and pharmacology. 1987, Vol 19, Num 1, pp 75-79, issn 0344-5704Article